Armata Pharmaceuticals, INC 8-K filings

Armata Pharmaceuticals has completed enrollment in its Phase 1b/2a diSArm study evaluating intravenous AP-SA02 for the treatment of Staphylococcus aureus bacteremia, with topline data expected in Q1 2025.

Armata Pharmaceuticals' Vice President, Corporate Controller, Richard Rychlik, concluded his employment effective September 30, 2024, with a separation agreement providing continued salary and benefits.

Armata Pharmaceuticals, Inc. has announced that its Vice President, Corporate Controller, Richard Rychlik, will be leaving the company effective September 30, 2024.

Armata Pharmaceuticals reports progress in its phage therapy clinical trials, including increased enrollment and promising early data for both its AP-PA02 and AP-SA02 candidates.

Armata Pharmaceuticals has appointed David House as its new Senior Vice President of Finance and Principal Financial Officer, effective August 16, 2024.

Armata Pharmaceuticals reported its second quarter 2024 financial results, highlighted by the completion of enrollment in a Phase 2 clinical study and receipt of additional non-dilutive funding.

Armata Pharmaceuticals has amended its employment agreement with Chief Medical Officer, Dr. Mina Pastagia, to reflect her current role and compensation.

Armata Pharmaceuticals held its annual shareholder meeting on June 12, 2024, where directors were elected, executive compensation was approved, and the company's auditor was ratified.

Armata Pharmaceuticals announced its first quarter 2024 financial results, highlighted by a $35 million secured credit agreement and progress in clinical trials.

Armata Pharmaceuticals has announced the date for its 2024 annual meeting of stockholders and established deadlines for shareholder proposals and director nominations.

Armata Pharmaceuticals announced its fourth quarter and full-year 2023 financial results, highlighting progress in clinical trials and manufacturing capabilities.

Armata Pharmaceuticals has secured a $35 million loan from Innoviva to fund clinical trials of its phage-based therapeutic candidates.